SAREPTA THERAPEUTICS, INC. Long-Term Debt, Maturity, Year Five
SAREPTA THERAPEUTICS, INC. (SRPT) had Long-Term Debt, Maturity, Year Five of $937.07 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2026-03-02
- 2025-12-31: Long-Term Debt, Maturity, Year Five $937.07M.
- 2025-09-30: Long-Term Debt, Maturity, Year Five $29.35M.
- 2022-12-31: Long-Term Debt, Maturity, Year Five $0.00.
- 2021-12-31: Long-Term Debt, Maturity, Year Five $0.00.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2025-12-31 | $937.07M 10-K · filed 2026-03-02 |
| 2025-09-30 | $29.35M 10-Q · filed 2025-11-06 |
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-01 |
| 2019-12-31 | $570.00M 10-K · filed 2020-02-26 |
| 2017-09-30 | $5.98M 10-Q · filed 2017-11-01 |
| 2016-12-31 | $172.00K 10-K · filed 2017-02-28 |
| 2015-12-31 | $172.00K 10-K · filed 2016-02-25 |
| 2014-12-31 | $171.00K 10-K · filed 2015-02-26 |
| 2013-12-31 | $114.00K 10-K · filed 2014-03-03 |
| 2012-12-31 | $108.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |